AI Summary
✦ ClarthaPrice Forecast
Revenue Forecast
₹ CrEPS Forecast
₹ / shareMulti-factor synthesis of 5 key dimensions
Analyst coverage unavailable
Fundamentals
Fundamentals institutional score is 25 using growth durability 25.3.
Valuation
No valid valuation metrics were supplied.
Analyst Consensus
No usable analyst target or recommendation data was available.
Technical Structure
This data source has not been supplied for the decision payload.
Market Sentiment
Recent news flow is balanced or not decisive enough to tilt the tape. Based on 1 recent ticker-linked news items.
Signal Summary
Market intelligence remains Cautious. Available evidence provides partial support, while fundamentals and market sentiment remain considerations.
Composite weights: Fundamentals 25%, Valuation 20%, Analyst Consensus 20%, Technical Structure 20%, Market Sentiment 15%.
Key Data Points
Important Note: This is market intelligence, not investment advice. Always conduct your own research and consider your financial goals and risk tolerance.
Valuation Metrics
Forward outlook is unavailable because live next-12-month estimate data is not available for this ticker right now.
Historical valuation metrics are unavailable for this ticker right now.
Peers & Comparison
Sector: Healthcare
| Company | Rev. Growth | Margin | P/E | vs Avg | 52W Perf. |
|---|---|---|---|---|---|
SUN PHARMACEUTICAL IND L SUNPHARMAPharma | +10.5% | 20.2% | 38.6x Fair | +13% vs avg | +20.9% |
CIPLA LTD CIPLAPharma | +3.5% | 12.0% | 35.2x Fair | +3% vs avg | -2.7% |
DR. REDDY S LABORATORIES DRREDDYPharma | -5.6% | 10.0% | 29.2x Fair | -15% vs avg | -3.9% |
Curis Lifesciences is compared against the Healthcare cohort. Peers include SUN PHARMACEUTICAL IND L, CIPLA LTD, DR. REDDY S LABORATORIES — selected based on business model, industry classification, market cap similarity, and business theme alignment.
Financials
Real statement data for revenue, earnings quality, conversion, and balance-sheet coverage. Monetary values are shown in Rs crore.
Latest revenue
₹33 CrMar 2026Latest net profit
₹2.71 CrMar 2026Latest EPS
₹3.35Mar 2026Net margin
15.7%Mar 2026Performance
Bars show revenue and net profit. The line shows net margin.
- Revenue
- Net income
- Net margin %
Earnings
Revenue is shown in crores. EPS is rupees per share.
- Revenue
- EPS
Revenue to profit conversion
Bridge from operating numbers to profit for the latest reported period.
Latest reported period: Mar 2026
Debt level and coverage
Debt, cash and free cash flow compared on the same crore scale.
- Debt
- Free cash flow
- Cash & equivalents
Results
| Metric | Sep 2024 | Mar 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|
| Sales + | 15.90 | 34.36 | 27.91 | 32.72 |
| Expenses + | 12.09 | 27.43 | 21.92 | 27.58 |
| Operating Profit | 3.81 | 6.93 | 5.99 | 5.14 |
| OPM % | 23.96% | 20.17% | 21.46% | 15.71% |
| Other Income + | -0.02 | 0.05 | 0.00 | 0.27 |
| Interest | 0.50 | 0.61 | 0.43 | 0.71 |
| Depreciation | 0.34 | 0.34 | 0.34 | 0.35 |
| Profit before tax | 2.95 | 6.03 | 5.22 | 4.35 |
| Tax % | 25.42% | 33.67% | 19.35% | 37.70% |
| Net Profit + | 2.20 | 4.00 | 4.21 | 2.71 |
| EPS in Rs | 44.00 | 6.74 | 7.09 | 3.35 |
| Raw PDF |
All values in ₹ Crores unless otherwise stated. Source: Screener Master (Standalone).
Events Timeline
Quarterly Compliance Report on Corporate governance - within 21 days from the end of the quarter